Back to companies

Emergent BioSolutions Inc: Overview

Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Headquarters United States of America

Address 2273 Research Blvd, Suite 400, Rockville, Maryland, 20850


Telephone 1 301 7951800

No of Employees 2,416

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange EBS (NYSE)

Revenue (2021) $1.8B 15.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -24.3% (2021 vs 2020)

Market Cap* $1.5B

Net Profit Margin (2021) XXX -34.4% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

100+

Clinical Trials

Determine Emergent BioSolutions Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Pipeline Drugs

Identify which of Emergent BioSolutions Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Emergent BioSolutions Inc’s relevant decision makers and contact details.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Marketed Drugs

Understand Emergent BioSolutions Inc’s commercialized product portfolio to stay one step ahead of the market.

11+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Emergent BioSolutions Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

8

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

2

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

Investigators

Review investigator profiles and find information on trial contacts across Emergent BioSolutions Inc, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

1

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
BioThrax - Anthrax Vaccine ACAM2000
ACAM2000 - Smallpox (Vaccinia) Vaccine Anthrasil
Anthrasil - Inhalational Anthrax Bat
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In May, the company entered into an agreement to acquire exclusive worldwide rights to TEMBEXA (brincidofovir) from Chimerix Inc, a biotechnology company.
2022 Others In March, the company initiated the Phase 1 study for evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN) aginst the treatment of acute cyanide poisoning.
2021 Others In December, the company initiated Phase 1 study on evaluating the safety, tolerability, and immunogenicity of the universal influenza vaccine candidate against influenza A viruses.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Emergent BioSolutions Inc Novartis AG Merck & Co Inc GSK plc Amgen Inc
Headquarters United States of America Switzerland United States of America United Kingdom United States of America
City Rockville Basel Whitehouse Station Brentford Thousand Oaks
State/Province Maryland - New Jersey - California
No. of Employees 2,416 110,000 68,000 90,096 24,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Zsolt Harsanyi, Ph.D. Chairman Executive Board 2022 78
Robert G. Kramer President; Director; Chief Executive Officer Executive Board 2019 64
Richard S. Lindahl Treasurer; Executive Vice President; Chief Financial Officer Senior Management 2018 58
Adam R. Havey Chief Operating Officer; Executive Vice President Senior Management 2021 51
Howard Anderson Senior Vice President; Chief Information Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer